Particle LSUGS
new particle slug
new particle slug body
new particle slug 2
new particle slug2
new particle slug3
new particle slug3
Particle LSUGS
new particle slug body
new particle slug2
new particle slug3
Black Americans are less likely than white Americans to say they plan to get a flu vaccine this year, and significantly less likely to say they'll take a first-generation coronavirus vaccine, according to numbers from the latest edition of the Axios-Ipsos Coronavirus Index.
Why it matters: Black Americans have suffered disproportionately from COVID-19, which means they also stand to benefit from a successful vaccine. But a legacy of medical mistreatment, systematic racism in health care and targeted efforts by anti-vaxxers means that a wide trust gap needs to be closed first.
Details: 49% of Black Americans say they are somewhat or very likely to get a flu shot this year, compared 65% of white Americans and 60% of Hispanics.
How it works: Experts say that Black Americans' vaccine reluctance is due largely to racism, both past and present.
Context: Anti-vaxxers have alsobegun specifically targeting Black communities and Black Lives Matter events in an effort to spread misinformation about vaccine safety.
The bottom line: Black Americans desperately need an effective coronavirus vaccine, but if the medical establishment is going to close the gap in trust, it needs to engage to directly engage with the Black community before a vaccine is made available.
Methodology: This Axios/Ipsos Poll was conducted August 21-24 by Ipsos’ KnowledgePanel®. This poll is based on a nationally representative probability sample of 1,084 general population adults age 18 or older.
A less visible but still massive trauma caused by the coronavirus is becoming clear: our mental health is suffering with potentially long-lasting consequences.
Why it matters: Mental health disorders that range from schizophrenia to depression and anxiety exert a severe cost on personal health and the economy. Addressing that challenge may require out-of-the-box solutions.
What's happening: During the early stages of the COVID-19 pandemic in the U.S., there were significant increases in acute stress and depressive symptoms, according to a study published earlier this week in Science Advances.
Context: A deep body of scientific research shows that experiencing collective traumas like a mass shooting or a natural disaster can lead to lasting mental health damage. But what sets the pandemic apart is its global scope and its sheer length.
The trauma of getting sick, seeing loved ones get sick, or losing a job will adversely affect the mental health of even the most redoubtable individual. But the unique nature of the pandemic stresses us in other ways.
More than almost any other condition, mental health disorders have remained stubbornly resistant to the interventions of modern medicine and, according to one estimate, are set to cost the global economy $16 trillion by 2030.
What's next: That's an approach brain-interface startups like Elon Musk's Neuralink and NeuroOne are beginning to explore.
The catch: We're still far from fully understanding the brain as well as we do other organs like the heart, and if brain interfaces are ever going to be used for more common conditions like depression, they need to be much less invasive and much more durable.
The bottom line: Given the open-ended trauma of the pandemic and the general chaos of 2020, feeling depressed is more logical than pathological. But we desperately need better solutions to the lasting pandemic that is mental illness, even after COVID-19 is finally vanquished.
The Food and Drug Administration granted emergency authorization Tuesday to Ellume's over-the-counter antigen COVID-19 test for fully at-home use.
Why it matters: Once available, a person in theory would be able to buy the test in a drug store, swab their nose, and run the test for results in about 20 minutes.
The big picture: Currently, home kits that test for the novel coronavirus either still need a prescription or require swabs be shipped to a lab, which could take days for results.
How it works: The rapid test can be used by symptomatic and asymptomatic users ages 2 years and above. This type of test detects fragments of proteins of the SARS-CoV-2 virus from a nasal swab sample.
Yes, but: Like all other antigen tests, "a small percentage of positive and negative results from this test may be false," the FDA notes.
There's no doubt about the outcome — Congress will ratify Joe Biden's election win and he'll be sworn in on Jan. 20 — but that won't stop today's political theater that may drag late into the night.
Details: The House of Representatives and Senate will meet in joint session in the House chamber at 1 p.m. ET to officially count and certify the 538 electoral votes ratified in all 50 states and the District of Columbia.
Why it matters: The debate won't change the election results. There are more than enough Republican senators and members of the House who have indicated they will recognize the certified votes from the states to ensure a majority vote to reject the objections.
How it works: Vice President Mike Pence will serve as presiding officer. If he decides to delegate the job, which is not expected, it would fall to Sen. Chuck Grassley as the Senate President Pro Tempore.
Trump has been pressuring Pence to overturn the election results, but that is not within Pence's ceremonial powers.
Timing: The process is expected to continue late into Wednesday evening, and could spill into Thursday depending on how long lawmakers want to draw out the objection process.
Go deeper: Read the Congressional Research Service guide to counting the votes